The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.

Giuseppe Saglio

Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Timothy P. Hughes

Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis

Research Funding - Bristol-Myers Squibb; CSL Limited; Novartis

Richard A. Larson

Consultant or Advisory Role - Novartis

Research Funding - Novartis

Surapol Issaragrilsil

No relevant relationships to disclose

Anna G. Turkina

Consultant or Advisory Role - Bristol-Myers Squibb; Novartis

Honoraria - Bristol-Myers Squibb; Novartis

Juan Luis Steegmann

Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer

Honoraria - Bristol-Myers Squibb; Novartis; Pfizer

Jose L. Lopez

No relevant relationships to disclose

Chiaki Nakaseko

No relevant relationships to disclose

Matt E. Kalaycio

Research Funding - Novartis

Francoise Huguet

Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi

Expert Testimony - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi

Charisse N. Kemp

Employment or Leadership Position - Novartis

Xiaolin Fan

Employment or Leadership Position - Novartis

Hans D. Menssen

Employment or Leadership Position - Novartis

Hagop M. Kantarjian

Research Funding - Bristol-Myers Squibb; Novartis; Pfizer

Andreas Hochhaus

Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer